Silver Spring, Maryland, USA, September 3, 2026
The U.S. Food and Drug Administration (FDA) has approved Zanvastro (zilganersen) injection for the treatment of Alexander disease in pediatric and adult patients, marking the first FDA-approved treatment for the rare and progressive neurological disorder. The approval represents a significant milestone in rare disease drug development, as Zanvastro is also the first therapy designed to directly address the abnormal protein buildup underlying Alexander disease. The treatment was developed by Ionis Pharmaceuticals, Inc., and uses an antisense oligonucleotide approach to reduce production of abnormal glial fibrillary acidic protein (GFAP) before it can accumulate and contribute to nervous-system damage.
Zanvastro Targets the Underlying Cause of Disease
Alexander disease is a rare neurological disorder associated with mutations in the gene responsible for producing GFAP, a protein found in cells that provide structural and functional support within the nervous system. When GFAP is abnormal, it can accumulate and progressively damage the brain and nervous system. The condition affects fewer than one in one million people and may cause severe symptoms including seizures, developmental regression, difficulty walking, muscle weakness and increased intracranial pressure. Historically, patients have had no approved disease-targeting treatment and have primarily received supportive care as the disease progressed. Zanvastro introduces a targeted molecular approach to this unmet medical need. As an antisense oligonucleotide, the therapy works by reducing production of abnormal GFAP, with the goal of limiting the protein accumulation associated with disease progression. The treatment is administered through an injection into the spinal canal every three months by a trained healthcare professional. This mechanism makes the approval particularly important for the broader field of RNA-targeted therapeutics, demonstrating how antisense technology can be applied to rare neurological disorders driven by abnormal protein production.
Clinical Data Support Broad Pediatric and Adult Use
The FDA evaluated Zanvastro’s safety and efficacy using evidence from a multicenter, randomized, controlled clinical study involving 49 pediatric and adult patients aged two years and older, together with an open-label substudy involving four patients younger than two years. Because Alexander disease is exceptionally rare and affects patients across different stages of development, the FDA considered evidence supporting an indication spanning infancy through adulthood. Among patients aged five years and older who had measurable walking difficulties at baseline, participants receiving Zanvastro demonstrated significantly better walking speed at 61 weeks compared with patients who received no treatment. For children aged two to four years, researchers used a broader motor-function assessment covering activities such as standing, walking, running and jumping, because walking speed alone is less reliable in this age group. Children treated with Zanvastro improved on this assessment, while the control group experienced decline. For patients younger than two years, direct clinical evidence was more limited because of the disease’s rarity and the absence of a concurrent control group. Pharmacokinetic modeling and available safety information supported extending the indication to these youngest patients.
Advertisement
FDA Approval Highlights Rare Disease Innovation
The FDA approval also underscores the role of specialized regulatory pathways in advancing treatments for rare and serious neurological diseases. Zanvastro received Orphan Drug, Fast Track, Breakthrough Therapy, Rare Pediatric Disease and Priority Review Voucher designations during its development, reflecting the significant unmet medical need associated with Alexander disease and the potential importance of developing a disease-modifying treatment. Safety monitoring will remain important following approval. The FDA identified vomiting, back pain, cough, headache and post-lumbar puncture syndrome among the most common adverse effects. Aseptic meningitis has also been reported, meaning patients and caregivers should promptly discuss symptoms consistent with meningitis with healthcare professionals. The treatment’s administration through the spinal canal further emphasizes the importance of appropriate clinical expertise and monitoring during therapy. The approval of Zanvastro represents a major advance for the Alexander disease community and provides the first approved therapeutic option aimed directly at the biological mechanism driving the disorder. More broadly, the decision highlights the growing potential of antisense medicines and molecularly targeted therapies to address rare diseases for which conventional treatment approaches have historically been limited.
Source: FDA press release
